卫宁健康科技集团股份有限公司 内幕信息知情人登记管理制度 第一章 总则 第一条 为进一步规范卫宁健康科技集团股份有限公司（以下简称"公司" 或"本公司"）内幕信息管理行为，加强公司内幕信息保密工作，维护信息披露 公平原则，根据《中华人民共和国公司法》《中华人民共和国证券法》（以下简 称"《证券法》"）《上市公司信息披露管理办法》《深圳证券交易所创业板股 票上市规则》《上市公司监管指引第5号——上市公司内幕信息知情人登记管理 制度》等相关法律法规以及《卫宁健康科技集团股份有限公司章程》的相关规定， 并结合本公司实际情况，制定本制度。 第二条 公司董事会是内幕信息的管理机构，董事会办公室负责内幕信息的 日常管理工作。对外报送的文件、光盘等涉及内幕信息和信息披露内容的资料， 须经相关部门负责人批准、公司董事会秘书审核同意（并视信息重要程度报送公 司董事会审核），方可对外报道、传送。 第三条 公司董事、高级管理人员和公司各部门、分（子）公司都应做好内 幕信息的及时报告、管理和保密工作，不得泄露内幕信息，不得进行内幕交易或 配合他人操纵公司证券交易价格。 第二章 内幕信息及内幕信息知情人员的范围 第四条 本制度所指内幕 ...

卫宁健康科技集团股份有限公司 对外担保管理制度 第一章 总则 第一条 为了规范卫宁健康科技集团股份有限公司（以下简称"公司"）的对 外担保行为，防范对外担保风险，确保公司资产安全和保护投资者的合法权益， 根据《中华人民共和国公司法》《中华人民共和国民典法》《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》等有关法律法规、规范性文件以及《卫宁健康科技集团股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，结合公司的实际情况，特制定 本制度。 第二条 本制度适用于公司及控股子公司。 第三条 本制度所称对外担保是指公司以自有资产、信誉为其他单位或个人 提供的保证、资产抵押、质押以及其他担保形式，包括公司对控股子公司的担保。 公司以自有资产为自身债务提供抵押、质押或其他形式的担保，不属于对外 担保，参照相关法律法规执行。 第四条 公司为控股股东、实际控制人及其关联方提供担保的，控股股东、 实际控制人及其关联方应当提供反担保。 第五条 公司对外担保实行统一管理，未经公司董事会或股 ...

卫宁健康科技集团股份有限公司 募集资金管理办法 第一章 总则 第一条 为进一步加强卫宁健康科技集团股份有限公司（以下简称"公司"） 募集资金的管理和运用，保护投资者的利益，依据《中华人民共和国公司法》《中 华人民共和国证券法》《上市公司募集资金监管规则》《深圳证券交易所创业板 股票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市 公司规范运作》等规定以及《卫宁健康科技集团股份有限公司章程》，结合公司 实际情况，特制定本办法。 募集资金投资项目通过公司的子公司或公司控制的其他企业实施的，则该子 公司或控制的其他企业应遵守本办法。 募集资金投资项目采用与他人组建合资公司的方式建设时，该合资公司应当 参考本办法制定相应的募集资金管理办法。 第二条 本办法所称募集资金，是指公司通过发行股票或其他具有股权性质 的证券，向投资者募集并用于特定用途的资金，但不包括公司实施股权激励计划 募集的资金。 第三条 保荐机构或者独立财务顾问在持续督导期内应当对公司募集资金管 理事项履行保荐职责，按照相关规定开展对公司募集资金管理的持续督导工作。 募集资金投资境外项目的，公司及保荐机构应当采取有效措施，确保境外项目募 ...

卫宁健康科技集团股份有限公司 投资者关系管理制度 第一章 总则 第一条 为了进一步加强卫宁健康科技集团股份有限公司（以下简称"公司"） 与投资者和潜在投资者（以下统称"投资者"）之间的沟通，促进投资者对公司 的了解，进一步完善公司法人治理结构，实现公司价值最大化和股东利益最大化， 根据《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易所上 市公司自律监管指引第2号-创业板上市公司规范运作》等有关法律、法规和《卫 宁健康科技集团股份有限公司章程》的规定，结合公司实际情况，制定本制度。 （二）平等性原则：公司开展投资者关系管理活动，应当平等对待所有投资 者，尤其为中小投资者参与活动创造机会、提供便利； （三）主动性原则：公司应当主动开展投资者关系管理活动，听取投资者意 见建议，及时回应投资者诉求； 1 （四）诚实守信原则：上市公司在投资者关系管理活动中应当注重诚信、坚 守底线、规范运作、担当责任，营造健康良好的市场生态。 第四条 投资者关系管理的目的： （一）形成尊重投资者及投资市场的企业文化； 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动 交流和诉求处理等工作，加强与投资者之间 ...

卫宁健康科技集团股份有限公司 累积投票制实施细则 第一章 总 则 第一条 为维护中小股东的利益，规范公司法人治理结构，规范公司选举董 事行为，根据《上市公司治理准则》和《卫宁健康科技集团股份有限公司章程》 （以下简称"《公司章程》"），并结合公司具体情况制定本细则。 第二条 本细则所称累积投票制主要适用于董事的选举，即：在选举两个以 上的董事席位时，股东拥有的投票权等于该股东持有的股份数与待定董事总人数 的乘积。股东既可以用所有的投票权集中投票选举一位候选董事，也可以分散投 票数位候选董事，董事一般由获得投票数较多者当选。 第三条 本实施细则所称的"董事"包括独立董事和非独立董事。由职工代 表担任的董事由公司职工民主选举产生或更换，不适用本实施细则的相关规定。 第四条 公司董事会、独立董事、符合条件的股东可以向公司股东征集其在 股东会上的投票权，征集人应在委托权限范围内，代表股东投票选举董事，详细 规定另行制定。 第五条 公司通过累积投票制选举产生的董事，其任期不实施交错任期制， 即届中因缺额而补选的董事任期为该届余任期限，不跨届任职。 第二章 董事候选人的提名 第六条 公司依照《公司章程》规定的方式和程序确 ...

Investment Rating - The report maintains a "Buy" investment rating for the company [2][7]. Core Insights - The company is experiencing short-term performance pressure, with a significant decline in revenue and net profit due to deferred customer demand and ongoing product upgrades [4]. - The introduction of new AI-driven products, such as WiNGPT 3.0 and WiNEX Copilot 2.2, is expected to enhance market competitiveness and drive future revenue growth [5][6]. - The company has a strong focus on integrating AI into its healthcare solutions, which is anticipated to contribute positively to its financial performance in the coming years [6][7]. Financial Performance Summary - In the first half of 2025, the company reported revenue of 839 million yuan, a year-on-year decrease of 31.43%, and a net profit of -118 million yuan, down 491.04% [4]. - Revenue forecasts for 2025-2027 are projected at 3.144 billion, 3.585 billion, and 4.088 billion yuan, respectively, with corresponding EPS of 0.18, 0.22, and 0.27 yuan [7][9]. - The company is expected to see a revenue growth rate of 13.0% in 2025, followed by 14.0% in 2026 and 14.1% in 2027 [9][11]. Market Position and Strategy - The company has established a strong foothold in the AI healthcare sector, having deployed AI solutions in nearly 150 medical institutions [5][6]. - The ongoing development of AI capabilities is seen as a key driver for future business growth, with a focus on enhancing clinical applications and operational efficiency [6].

Core Insights - The medical information technology industry is undergoing significant consolidation, with major acquisitions signaling a shift in the market dynamics after a period of rapid growth [1][2][3] - The demand for medical IT solutions has decreased as most hospitals have met previous regulatory requirements, leading to a more cautious approach in project approvals and increased competition among firms [3][4][6] - The integration of AI and new technologies is expected to drive the next phase of growth in the medical IT sector, creating opportunities for companies that can adapt to changing market needs [9] Industry Trends - Recent acquisitions include the purchase of medical consulting firm Yice Medical Management by Xisoft Technology, indicating a trend where larger firms seek to enhance their service offerings by integrating complementary smaller companies [1][7] - The medical IT industry experienced a boom from 2018 to mid-2023, driven by regulatory support and technological advancements, but has since faced challenges due to market saturation and budget constraints in hospitals [2][3][8] - The push for digital transformation in hospitals has led to a demand for more comprehensive solutions that integrate various operational aspects, moving beyond simple IT services [4][6] Market Dynamics - The competitive landscape is shifting as smaller firms struggle to meet the new demands for standardized solutions, while larger firms are better positioned to capitalize on these changes through strategic acquisitions [6][8] - The focus on cost control and efficiency in hospitals has made it more challenging for medical IT companies to secure contracts, as decision-makers are now more cautious and selective [3][6] - The ongoing consolidation in the industry is expected to enhance the bargaining power of remaining firms and may lead to a more concentrated market structure [8][9]

Group 1 - The first Medical Artificial Intelligence Conference (MAIC2025) will open on September 26 in Shandong, focusing on the integration of AI in the healthcare sector and aligning with China's health and innovation strategies [1] - The conference is positioned as a key platform for capital and industry connection amid the rapid expansion of the medical AI market [1] - The event's location in Jinan highlights the regional industrial layout, as Jinan is a core area for the transformation of new and old growth drivers, building an "AI + healthcare" industry cluster [1] Group 2 - The National Health Commission's guidelines on the classification of AI medical software products and the establishment of innovation funds across various regions are supporting the development of medical AI [1] - Wanda Information will showcase its latest achievements and typical application cases in the field of medical artificial intelligence, focusing on "AI + health management" [1] - Weining Health will present a series of innovative products, including the doctor-exclusive AI workstation WiNBOT, the next-generation smart hospital system WiNEX, the medical large model WiNGPT, and the healthcare intelligent assistant WiNEX Copilot [1]

Core Insights - The company is focusing on the continuous iteration and evolution of its new generation product, WiNEX, to better meet overall user needs [2] - WiNEX has accumulated hundreds of users and has entered the stage of mass promotion and application, with ongoing improvements in delivery efficiency [2] Product Development - WiNEX is categorized as a standardized product that will undergo continuous updates [2] - The company has established a research and development technology platform to support rapid software system development and operation [2] - The design is cloud-based, enabling a new research and development model that supports both online and offline integration [2] User Engagement - The company aims to enhance development efficiency to better cater to personalized user requirements [2]

Core Insights - The event "2025 Shanghai Listed Companies Collective Reception Day and Mid-Year Performance Briefing" was held on September 19, showcasing the progress of various companies, including Weining Health [1] - Weining Health's Chairman, Zhou Wei, highlighted the deployment of the WiNGPT Copilot intelligent assistant in nearly 150 hospitals, covering over 100 scenarios such as smart consultations and medical record quality control [1] Company Overview - Weining Health, founded in 2004, integrates research and development, sales, and technical services to provide comprehensive solutions [1] - The company focuses on healthcare information technology solutions, aiming to enhance patient experience and health standards [1] - Through continuous technological innovation, Weining Health develops products and solutions tailored to various application scenarios, covering smart hospitals, regional health, grassroots health, public health, medical insurance, and health services [1]